Steven Zhao

@AberdeenEpi @PhysioWillGreg @KarlGaffney1 @RheumatologyUK @LindsayTurnerPM So true. We were joyous the rest of the video, except this frame 😅

Today is the day! LAUNCH of the BSR guideline for axial spondyloarthritis - a blog on the BSR news page rheumatology.org.uk/news - podcast talkingrheumatology.buzzsprout.com - video on the BSR youtube channel youtube.com/watch?v=p-b1iN… - and the guideline itself doi.org/10.1093/rheuma…

📢 We are delighted to share our newly-updated clinical guideline for the management of axial spondyloarthritis! Read more: bit.ly/3EdQnei @NASSexercise @BritspaUK #guidelines #rheumatology #axSpA

📢Do you work in #Rheumatology or #Dermatology in the UK? Please help us understand the impact of #obesity on #psoriasis and #PsoriaticArthritis 👉🏽app.onlinesurveys.jisc.ac.uk/s/leeds/second…

A great new resource for phenome-wide genetic explorations by the Estonian Biobank🇪🇪🧬 👉206,159 participants 👉GWASs for 4,884 ICD-10 diagnoses 👉2,127 unique GWAS loci 👉778 putatively novel locus-phenotype associations

A GWAS meta-analysis for sarcoidosis in 9,755 cases and 1,526,867 controls🧬 In diseases like sarcoidosis, where we know little about etiology, GWAS can be much more interesting, as they provide pathogenesis insights with potential for informing therapeutic strategies

#PhysicalActivity for those with chronic widespread pain & #fibromyalgia effective in ✅Reducing #pain & #depression ✅Enhancing quality of life 🔹Intense physical activity has strongest protective effect #MetaAnalysis 👉🏽dovepress.com/effect-of-phys…

*these results replicate an earlier candidate gene study of TYK2 and sarcoid sciencedirect.com/science/articl…

The largest #GWAS of #sarcoidosis to date identifies 28 susceptibility loci and implicates CCDC88 and #TYK2* genes. MR suggested causal roles of IL-23R and IL-2Rβ, and risk increasing role of #BMI. @Yuan_AS nature.com/articles/s4146…

This study compares #apremilast and #methotrexate (that have more similar efficacy for cutaneous psoriasis) to see if targeted therapy reduces PsA risk independent of skin control.

However, a key limitation is that IL-17/-23 inhibitors have superior efficacy for controlling cutaneous disease, the severity of which is an independent risk factor for PsA onset.

🚨#Apremilast (#Otezla) is associated with⬇️risk of #PsoriaticArthritis compared to #methotrexate among people with cutaneous #psoraisis (HR 0.85, 95%CI 0.79, 0.91). Research funded by @PsoriasisInfo sciencedirect.com/science/articl…

This research was funded by @PsoriasisInfo

🚨The incidence of #uveitis and #IBD in psoriatic disease, and vice versa, is not well described. This study shows, among other things, that uveitis and IBD incidences are higher in #PsA than cutaneous-only #psoriasis and higher in females than males. academic.oup.com/rheumatology/a…

🚨#Tofacitinib ⬆️ #cardiovascular & #cancer risk in RA. But how relevant is this risk to people with #AxialSpondyloarthritis or #PsoriaticArthritis? This study did not find⬆️risk of JAK compared to TNF/IL17 inhibitors in SpA. Funded by @PsoriasisInfo sciencedirect.com/science/articl…

Mendelian randomization (MR) has been criticized due to a flood of papers based on the output of a single R command. But MR can offer valuable insights into disease etiology and can be really fun Some interesting MR applications in examples from our work over the years 🧵 1/17

@doctorveera To me, this should reassure all the folks worried about therapeutic TNF inhibition causing cancer

Remarkable discovery of two human knockouts for Tumor Necrosis Factor alpha (TNF α) gene, who were found to be surprisingly healthy except for specific susceptibility to recurrent pulmonary tuberculosis infection. One aspect of this discovery that stands out for me is its therapeutic relevance. Infliximab is a TNF α monoclonal antibody, developed in the early 1990s, and approved for the treatment of Crohn's disease and rheumatoid arthritis in the late 1990s. In the phase III trial published in Lancet in 1999, the authors reported that one of the participants developed disseminated treatment-resistant tuberculosis and died. That was the first clue into possible links between TNF α deficiency and TB susceptibility in humans (thelancet.com/journals/lance…). There was a follow-up study of a larger trial data published two years later in NEJM that confirmed that indeed one of the rare adverse effects of infliximab is tuberculosis risk, and the report recommended physicians to screen patients for latent tuberculosis infection before initiating infliximab therapy. (nejm.org/doi/full/10.10…). More than 20 years later, now scientists are encountering humans naturally lacking TNF α and provide genetic evidence that TNF α deficiency indeed increase the risk for TB. But the most important thing is the authors also show that TNF α deficiency is not that dangerous as one might expect from animal studies. Except for the TB infection, the patients seem to be healthy. How amazing is that? This is another great example of how rare disease patients can inform drug development. Arias et al. Nature nature.com/articles/s4158…

🚨 Fully funded PhD opportunity! 🚨 Join the DigiRA project at the University of Manchester & improve adherence in RA! 💻 Interdisciplinary research 💡 Innovative healthcare solutions 📍 Manchester, UK 🔗 Apply now: findaphd.com/phds/project/b… #PhD #DigitalHealth #Rheumatology

BSR guidelines on biologic DMARDs will guide clinicians to provide the safest, most effective care for inflammatory arthritis. BSR members, please help us shape recommendations that meet today’s challenges by sharing your feedback here: bit.ly/4freinW